Bcal Diagnostics Limited · ASX:BDX
Bcal Diagnostics — Shareholder Meeting (October 2026)
19 slides from Bcal Diagnostics's shareholder meeting presentation, Oct 19, 2026
Slide 1: FY26 Annual General Meeting
rsonal use only FY26 Annual General Meeting Chair: Jayne Shaw Chief Executive Officer: Anne-Louise Arnett 19 October 2026
Slide 2: CEO's Address
rsonal use only CEO’s Address
Slide 3: Pioneering diagnostics for earlier cancer detection
An Australian health care company pioneering diagnostics for earlier cancer detection rsonal use only Our Purpose Our promise to patients Our Ambition Close the gaps in early cancer Simple, accessible blood testing to To become the trusted choice in detection. help patients and clinicians make early
Slide 4: New leadership to drive commercial scale-up
Anne-Louise (Annie) Arnett New leadership to drive commercial scale–up rsonal use only 25+ years in medical technology Senior commercial and operational leadership across diagnostics, capital equipment and regulated product portfolios. Built an ANZ business from inception GM ANZ at Arthrex: stood up
Slide 5: Evolution from a single test to a scalable platform
BCAL’s evolution from a single test to a scalable cancer diagnostics platform rsonal use only 2025 2026 2027 1 4 5+ BREASTESTplus Avantect® portfolio added Broader platform expansion Single-product business Pancreatic Ovarian Multi-cancer New indications including Monitoring for recurrence NATA Accr
Slide 6: Building an Australian portfolio of earlier cancer detection
BCAL is building an Australian portfolio of earlier cancer detection rsonal use only TEST INDICATION STATUS Strategic execution priorities BREASTESTplus Breast cancer rule-out Available now Diversify diagnostics portfolio Avantect® Pancreatic High-risk patients Available now Build awareness and educ
Slide 7: Three forces driving demand for early detection
Three forces driving demand for early detection rsonal use only 48% of Australian women aged 50–74 do not participate in routine breast screening.* 0 available early screening for pancreatic and ovarian cancers Today's tools work too late Diagnostics is going less invasive Consumers are taking charg
Slide 8: Evidence gets a test approved. Infrastructure gets it used.
Evidence gets a test approved. Infrastructure gets it used. rsonal use only Patient experience GP / Specialist Telehealth Blood Draw & Laboratory Results Report GP / Specialist Referral Collection Analysis Review Referral forms in Best EarlyDetection.com.au Collection through the BREASTEST plus - NA
Slide 9: Building the trust levers to bring the portfolio to patients
BCAL is building the trust levers to bring the portfolio to patients rsonal use only 1 Pathology networks 2 Ordering where doctors already work National collection and testing through Sonic Referral forms embedded in Best Practice and Medical Healthcare and Healius. BREASTESTplus available at Direct
Slide 10: The channel is starting to deliver early commercial traction
The channel is starting to deliver early commercial traction rsonal use only BREASTESTplus Avantect® Pancreatic & Ovarian EarlyDetection.com.au 93 $136k 53,017 pathology collection sites revenue since January~ June 2026 website visits since Jan ~June 2026 • 20 clinics and 90 doctors across NSW • 90
Slide 11: Large and growing global markets
Large and growing global markets rsonal use only US$20.1B1 US$4.93B2 US$1.54B3 Breast cancer diagnostics Pancreatic cancer diagnostics Ovarian cancer diagnostics 8% CAGR, reaching US$40.7B by 2034 7.2% CAGR 6.6% CAGR 2.86M Australian women a year are addressable by BREASTESTplus the pancreatic, ovar
Slide 12: The Australian market opportunity
The Australian market opportunity rsonal use only Opportunity MARKET SIZE BY PRODUCT LINE (AUSTRALIA) Price Opportunity Test line Opportunity ($) $1.8B (AUD) (population) BREASTESTplus – women 50+ $300 1.02M $306M BREASTESTplus – women 30 - 49 $300 0.38M $114M Avantect Pancreatic $1,495 0.45M $637M
Slide 13: Multiple pathways to extend the platform
Multiple pathways to extend the platform rsonal use only Genetic Signatures Strategic optionality US expansion pathway Licensing & portfolio Strategic investment / Future licensing/ partnership expansion platform exposure opportunities • Agreement signed to support • Avantect® Pancreatic and • 18.5%
Slide 14: Five priorities to scale the platform
Five priorities to scale the platform rsonal use only 1 1 2 3 4 5 Drive commercial Expand the product Capture clinical Expand Build for scale adoption portfolio evidence geographically • GP and specialist education • BREASTESTplus 2 launch • Publications and clinical • NATA accreditation and • Sonic
Slide 15: How BCAL is maturing from R&D to commercial growth
How BCAL is maturing from R&D to commercial growth rsonal use only A national early detection platform with multiple pathways to growth 1 National commercial infrastructure 4 Near-term catalysts already in motion Sonic, Healius, GP referral systems and telehealth BREASTESTplus 2 launch, US validatio
Slide 16: FY27 commercial & clinical milestones
FY27 commercial & clinical milestones rsonal use only Q2 Q3 FY27 BREASTESTplus 2 launch Q2 including NATA accreditation Launch Avantect® Multi-cancer and incorporate into referral and collection channels Expand BREASTESTplus 2 and further integrate into referral and collection channels Introduce a n
Slide 17: Board and Management
Board and Management rsonal use only Jayne Shaw Jonathan Trollip David Darling Dr John Hurrell Mark McConnell Chair Independent Non- Non-executive Director Non-executive Director Non-executive Director executive Director Anne-Louise Arnett Guy Robertson Kathy Koskiris Dr David Mark Michelle Blackwel
Slide 18: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by BCAL The forward-looking statements are based on information available to Not An Offer rsonal use only Diagnostics Ltd ABN 51 142 051 223 (BCAL or the Company). BCAL as at the date of this Presentation. Circumstances may change This Pr
Slide 19: Thank you
rsonal use only Thank you. For further Information Anne-Louise Arnett Chief Executive Officer Aarnett@bcaldiagnostics.com Information portal about early cancer detection. earlydetection.com.au Access telehealth appointments with medical professionals.
BCAL Diagnostics — Shareholder Meeting (October 2026) on 6ix